Accelerated bone maturation syndrome of the weaver type

1981 ◽  
Vol 137 (3) ◽  
pp. 329-333 ◽  
Author(s):  
P. H. Weisswichert ◽  
G. Knapp ◽  
E. Willich
Keyword(s):  
Bone Maturation ◽  
Accelerated Bone Maturation

scholarly journals Altered Sequence of Pubertal Changes and Accelerated Bone Maturation in A 10-Year-Old Japanese Boy with Nonendocrine Short Stature Treated with GH.

1994 ◽  
Vol 3 (Supple4) ◽  
pp. 125-127
Author(s):  
Seiji Sato ◽  
Makoto Anzo ◽  
Tsutomu Kamimaki ◽  
Maki Fukami ◽  
Nobutake Matsuo
Keyword(s):  
Short Stature ◽  
Bone Maturation ◽  
Old Japanese ◽  
Accelerated Bone Maturation

scholarly journals Short Stature, Accelerated Bone Maturation, and Early Growth Cessation Due to Heterozygous Aggrecan Mutations

2014 ◽  
Vol 99 (8) ◽  
pp. E1510-E1518 ◽  
Author(s):  
Ola Nilsson ◽  
Michael H. Guo ◽  
Nancy Dunbar ◽  
Jadranka Popovic ◽  
Daniel Flynn ◽  
...  
Keyword(s):  
Short Stature ◽  
Early Growth ◽  
Bone Maturation ◽  
Growth Cessation ◽  
Accelerated Bone Maturation

scholarly journals Nonclassic congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency

2004 ◽  
Vol 132 (suppl. 1) ◽  
pp. 106-108
Author(s):  
Maja Jesic ◽  
Milos Jesic ◽  
Silvija Sajic ◽  
Svjetlana Maglajlic ◽  
Svetislav Necic ◽  
...  
Keyword(s):  
Late Onset ◽  
Hydroxylase Deficiency ◽  
Bone Maturation ◽  
Hormone Synthesis ◽  
Constant Control ◽  
Mild Deficiency ◽  
One Year ◽  
21 Hydroxylase Deficiency ◽  
Accelerated Bone Maturation ◽  
Premature Pubarche

Nonclassic CAH, also termed as late onset of CAH, is a very mild form of 21-hydroxylase deficiency. The incidence of disease is estimated at 0.1% of population. Nonclassic CAH is usually diagnosed in the childhood before the age of 6 to 8 years as premature pubarche. The disease is not common in the infants and usually not before 6 to 8 months. This is a case report of 7-month female infant who was suspected of mild hyperandrogenism because of premature pubarche. The diagnosis was confirmed by mild basal elevation of 17-OHP (5.55 ng/ml) and characteristic hyper-response to ACTH, reaching values of 21 ng/ml, as well as accelerated bone maturation. The conventional treatment of NCAH was initiated, with glucocorticoid therapy (hydrocortisone) for one year and a half. After that period, our decision was to discontinue the hormonal therapy because of the impression that hyperandrogenism was mild (mild deficiency of the enzymes for steroid hormone synthesis). Child?s growth, development and maturation are under constant control.

scholarly journals Aromatase Inhibitor as Treatment for Severely Advanced Bone Age in Congenital Adrenal Hyperplasia: A Case Report

2019 ◽  
Vol 92 (3) ◽  
pp. 209-213
Author(s):  
Wesley J. Goedegebuure ◽  
Anita C.S. Hokken-Koelega
Keyword(s):  
Congenital Adrenal Hyperplasia ◽  
Adult Height ◽  
Corticosteroid Treatment ◽  
Bone Age ◽  
Adrenal Hyperplasia ◽  
Bone Maturation ◽  
Standard Dosage ◽  
Novel Treatment ◽  
Accelerated Bone Maturation ◽  
Androgen Levels

Introduction:Treatment with aromatase inhibitors (AI) is a potential novel treatment in patients with congenital adrenal hyperplasia (CAH) and advanced bone age (BA), to increase near adult height (NAH). Not much is known about the efficacy of AI treatment in CAH and how AI treatment will influence the management of corticosteroid treatment. Case Presentation:At the age of 6 years and 3 months, a boy with salt-losing CAH presented with a BA 7 years in advance. Treatment with an AI (exemestane) was initiated to decelerate bone maturation. We continued the standard dosage of corticosteroid treatment. Precocious puberty was treated with 4 years of gonadotropin-releasing hormone agonist, while AI treatment was continued until attainment of NAH. His NAH 177.7 cm (–0.8 SDS) was considerably higher than his predicted adult height of 151.3 cm (–4.6 SDS) at the start of AI treatment. The higher serum androgen levels during AI treatment did not result in short adult stature. Discussion/Conclusion:This report shows that AI treatment can adequately decelerate bone maturation, causing predicted adult height to increase significantly in patients of CAH with accelerated bone maturation. We suggest continuing the same corticosteroid dosage during AI treatment and accepting higher serum androgen levels.

scholarly journals Precocious puberty: how about the accelerated bone maturation?

2019 ◽  
Vol 54 (4) ◽  
pp. 776-780
Author(s):  
Dan N. PADURARU ◽  
◽  
Oana BOTEZAN ◽  
Alexandra BOLOCAN ◽  
Octavian ANDRONIC ◽  
...  
Keyword(s):  
Precocious Puberty ◽  
Bone Maturation ◽  
Accelerated Bone Maturation
Sign in / Sign up

Export Citation Format

Share Document